Literature DB >> 28691207

Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients.

Noriko Tsuruta1,2, Shinichi Imafuku1, Yutaka Narisawa2.   

Abstract

Psoriatic arthritis (PsA) is a spondyloarthritic condition mainly seen in patients with psoriasis. Psoriatic patients with plaques on the scalp, gluteal fold or nail lesions are known to develop PsA more frequently, but other markers for PsA have not yet been identified. To determine which psoriatic patients are at greatest risk of developing PsA, psoriasis vulgaris (PsV) patients who visited the Department of Dermatology, Fukuoka University Hospital in 2015 were enrolled. Patients with and without PsA were statistically compared with respect to age, sex, age at onset, body mass index (BMI), smoking and drinking habits, familial history of psoriasis and comorbidities. Of 331 patients (237 men, 94 women), 55 had PsA (17%; 39 men, 16 women). PsA patients had significantly higher frequencies of nail lesions (PsA vs PsV-only, 62% vs 29%; P < 0.0001) and hyperuricemia (PsA vs PsV-only, 22% vs 9%; P = 0.01). These were confirmed as independent risk factors for PsA by logistic regression analysis, with odds ratios of 5.05 for nail lesions (P < 0.0001) and 4.18 for hyperuricemia (P < 0.01). There was no difference in age at onset, sex, BMI and incidence of diabetes mellitus, hypertension or dyslipidemia. Hyperuricemia is also known to be more frequent in psoriatic subjects than the normal population. Uric acid crystals are a strong stimulator of innate immunity. Considering that none of our cohort had gouty arthritis, hyperuricemia may increase uric acid crystallization in and around joints, thereby inducing PsA in psoriatic subjects. Hyperuricemia appears to be an independent risk factor for PsA.
© 2017 Japanese Dermatological Association.

Entities:  

Keywords:  Japan; epidemiology; hyperuricemia; psoriasis; psoriatic arthritis

Mesh:

Year:  2017        PMID: 28691207     DOI: 10.1111/1346-8138.13968

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  12 in total

1.  Bone microstructure and volumetric bone mineral density in patients with hyperuricemia with and without psoriasis.

Authors:  D Simon; J Haschka; C Muschitz; A Kocijan; A Baierl; A Kleyer; G Schett; S Kapiotis; H Resch; M Sticherling; J Rech; R Kocijan
Journal:  Osteoporos Int       Date:  2020-01-10       Impact factor: 4.507

Review 2.  Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study.

Authors:  Francesco Caso; Antonio Del Puente; Francesca Oliviero; Rosario Peluso; Nicolò Girolimetto; Paolo Bottiglieri; Francesca Foglia; Carolina Benigno; Marco Tasso; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

3.  Assessment of serum and synovial fluid MMP-3 and MPO as biomarkers for psoriatic arthritis and their relation to disease activity indices.

Authors:  Mariela Geneva-Popova; Stanislava Popova-Belova; Velichka Popova; Kostadin Chompalov; Anastas Batalov
Journal:  Rheumatol Int       Date:  2022-06-16       Impact factor: 3.580

4.  Assessment of Crystals in the Synovial Fluid of Psoriatic Arthritis Patients in Relation to Disease Activity.

Authors:  Mariela Geneva-Popova; Stanislava Popova-Belova; Velicka Popova; Nikolay Stoilov
Journal:  Diagnostics (Basel)       Date:  2022-05-18

5.  The association of serum uric acid levels in psoriasis patients: A systematic review and network meta-analysis.

Authors:  Yuan Yuan; Ming Liu; WenHong Liu; Hua Du
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

6.  Predicting the Risk of Psoriatic Arthritis in Plaque Psoriasis Patients: Development and Assessment of a New Predictive Nomogram.

Authors:  Panpan Liu; Yehong Kuang; Li Ye; Cong Peng; Wangqing Chen; Minxue Shen; Mi Zhang; Wu Zhu; Chengzhi Lv; Xiang Chen
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

Review 7.  Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review.

Authors:  Michelle L M Mulder; Tamara W van Hal; Mark H Wenink; Hans J P M Koenen; Frank H J van den Hoogen; Elke M G J de Jong; Juul M P A van den Reek; Johanna E Vriezekolk
Journal:  Arthritis Res Ther       Date:  2021-06-14       Impact factor: 5.156

8.  Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat.

Authors:  L Messer; R Felten; L Widawski; T Fabacher; L Spielmann; J E Gottenberg; J Sibilia; P M Duret
Journal:  Clin Rheumatol       Date:  2022-01-20       Impact factor: 3.650

9.  Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis.

Authors:  Nuria Barbarroja; Iván Arias-de la Rosa; Clementina López-Medina; María Del Rosario Camacho-Sánchez; Ignacio Gómez-García; Antonio José Vélez-García; Alejandro Escudero-Contreras; Chary López-Pedrera; María Dolores López-Montilla; Eduardo Collantes-Estévez
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-10-16       Impact factor: 5.346

10.  Psoriasis epidemiology screening tool (PEST) is useful for the detection of psoriatic arthritis in the Japanese population.

Authors:  Ayako Setoyama; Yu Sawada; Natsuko Saito-Sasaki; Shun Ohmori; Daisuke Omoto; Kayo Yamamoto; Haruna Yoshioka; Etsuko Okada; Motonobu Nakamura
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.